4//SEC Filing
ADELMAN DANIEL C MD 4
Accession 0000899243-20-027460
CIK 0001631650other
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 9:20 PM ET
Size
8.1 KB
Accession
0000899243-20-027460
Insider Transaction Report
Form 4
ADELMAN DANIEL C MD
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock, $0.0001 par value
2020-10-02$11.45/sh+34,932$399,971→ 63,807 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-10-02−34,932→ 135,068 totalExercise: $11.45Exp: 2026-06-24→ Common Stock (34,932 underlying)
Footnotes (4)
- [F1]Includes 8,750 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F2]Includes 8,906 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F3]Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F4]Fully exercisable.
Documents
Issuer
Aimmune Therapeutics, Inc.
CIK 0001631650
Entity typeother
Related Parties
1- filerCIK 0001222037
Filing Metadata
- Form type
- 4
- Filed
- Oct 4, 8:00 PM ET
- Accepted
- Oct 5, 9:20 PM ET
- Size
- 8.1 KB